Cite
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma
MLA
Satoshi Kobayashi, et al. “A Prospective Observational Cohort Study of Lenvatinib as Initial Treatment in Patients with BCLC-Defined Stage B Hepatocellular Carcinoma.” BMC Cancer, vol. 22, no. 1, May 2022, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s12885-022-09625-x.
APA
Satoshi Kobayashi, Taito Fukushima, Makoto Ueno, Satoshi Moriya, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Shunji Hirose, Tatehiro Kagawa, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Michihiro Suzuki, Haruki Uojima, Hisashi Hidaka, Chika Kusano, Motoko Suzuki, & Manabu Morimoto. (2022). A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma. BMC Cancer, 22(1), 1–9. https://doi.org/10.1186/s12885-022-09625-x
Chicago
Satoshi Kobayashi, Taito Fukushima, Makoto Ueno, Satoshi Moriya, Makoto Chuma, Kazushi Numata, Kota Tsuruya, et al. 2022. “A Prospective Observational Cohort Study of Lenvatinib as Initial Treatment in Patients with BCLC-Defined Stage B Hepatocellular Carcinoma.” BMC Cancer 22 (1): 1–9. doi:10.1186/s12885-022-09625-x.